

Palmoplantar Keratoderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/P8F4831A86EDEN.html>

Date: May 2024

Pages: 136

Price: US\$ 6,499.00 (Single User License)

ID: P8F4831A86EDEN

Abstracts

The 7 major palmoplantar keratoderma markets are expected to exhibit a CAGR of 2.19% during 2024-2034.

The palmoplantar keratoderma market has been comprehensively analyzed in IMARC's new report titled "Palmoplantar Keratoderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Palmoplantar keratoderma (PPK) is a rare dermatological condition characterized by the thickening of the skin on the palms of the hands and the soles of the feet. This disease falls under the category of hereditary keratinization disorders and can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Individuals suffering from the ailment often experience a range of symptoms, including the development of thick, rough, and calloused skin on their palms and soles. This thickening of the skin can lead to discomfort, pain, and reduced dexterity due to the abnormal accumulation of keratin, a protein that provides strength and protection to the skin. In some cases, PPK may also be associated with additional indications, such as blisters, fissures, and redness, further impacting the quality of life. The diagnosis of the disorder involves a clinical examination of the affected areas, taking into consideration the patient's medical history and any family history of similar skin conditions.

The escalating prevalence of genetic mutations affecting proteins responsible for skin cell regulation, particularly those involving keratin, is primarily driving the palmoplantar keratoderma market. In addition to this, the inflating utilization of advanced therapeutic approaches, including topical retinoids, keratolytics, and emollients, aimed at alleviating symptoms and preventing the progression of the disorder, is also creating a positive outlook for the market. Moreover, the widespread adoption of tailored interventions like

phototherapy and systemic treatments, as they are effective in managing the condition's severity and improving patients' quality of life, is further bolstering the market growth. Apart from this, the rising usage of minimally invasive procedures, such as laser therapy and microdermabrasion, that target the thickened skin areas by stimulating the production of collagen and promoting skin remodeling is acting as another significant growth-inducing factor. Additionally, the escalating application of physical and occupational therapies, which help in enhancing mobility and minimizing discomfort associated with the disorder, is also augmenting the market growth. Furthermore, the emerging popularity of gene therapy, involving the introduction of functional genetic components to correct or replace malfunctioning genes responsible for PPK, is expected to drive the palmoplantar keratoderma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the palmoplantar keratoderma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for palmoplantar keratoderma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the palmoplantar keratoderma market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the palmoplantar keratoderma market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the palmoplantar keratoderma market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current palmoplantar keratoderma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the palmoplantar keratoderma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the palmoplantar keratoderma market across the

seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the palmoplantar keratoderma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of palmoplantar keratoderma across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of palmoplantar keratoderma by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of palmoplantar keratoderma by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with palmoplantar keratoderma across the seven major markets?

What is the size of the palmoplantar keratoderma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of palmoplantar keratoderma?

What will be the growth rate of patients across the seven major markets?

Palmoplantar Keratoderma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for palmoplantar keratoderma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the palmoplantar keratoderma market?

What are the key regulatory events related to the palmoplantar keratoderma market?

What is the structure of clinical trial landscape by status related to the palmoplantar keratoderma market?

What is the structure of clinical trial landscape by phase related to the palmoplantar keratoderma market?

What is the structure of clinical trial landscape by route of administration related to the palmoplantar keratoderma market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PALMOPLANTAR KERATODERMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 PALMOPLANTAR KERATODERMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 PALMOPLANTAR KERATODERMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (?2018-2034?)
- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 PALMOPLANTAR KERATODERMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PALMOPLANTAR KERATODERMA - UNMET NEEDS

10 PALMOPLANTAR KERATODERMA - KEY ENDPOINTS OF TREATMENT

11 PALMOPLANTAR KERATODERMA - MARKETED PRODUCTS

- 11.1 List of Palmoplantar Keratoderma Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 PALMOPLANTAR KERATODERMA - PIPELINE DRUGS

12.1 List of Palmoplantar Keratoderma Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. PALMOPLANTAR KERATODERMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PALMOPLANTAR KERATODERMA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 PALMOPLANTAR KERATODERMA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Palmoplantar Keratoderma - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Palmoplantar Keratoderma - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Palmoplantar Keratoderma - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Palmoplantar Keratoderma - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

- 15.3.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Palmoplantar Keratoderma - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Palmoplantar Keratoderma - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Palmoplantar Keratoderma - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Palmoplantar Keratoderma - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Palmoplantar Keratoderma - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Palmoplantar Keratoderma - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Palmoplantar Keratoderma - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Palmoplantar Keratoderma - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Palmoplantar Keratoderma - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Palmoplantar Keratoderma - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)

- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Palmoplantar Keratoderma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Palmoplantar Keratoderma - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Palmoplantar Keratoderma - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Palmoplantar Keratoderma - Access and Reimbursement Overview

16 PALMOPLANTAR KERATODERMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PALMOPLANTAR KERATODERMA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 PALMOPLANTAR KERATODERMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Palmoplantar Keratoderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/P8F4831A86EDEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P8F4831A86EDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

